<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> is one of the most frequent <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> diseases </plain></SENT>
<SENT sid="1" pm="."><plain>For patients with this type of <z:e sem="disease" ids="C0345904" disease_type="Neoplastic Process" abbrv="LCC">cancer, liver</z:e> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> are the main cause of <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, new therapeutic approaches are urgently needed to improve the outcomes </plain></SENT>
<SENT sid="3" pm="."><plain>We found that both <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein levels of tissue inhibitor of metalloproteinase-3 (TIMP3) were decreased significantly in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> tissue when compared with <z:mpath ids='MPATH_458'>normal</z:mpath> mucosa, suggesting that decrease of TIMP3 expression was correlated with malignant behavior of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We evaluated the power of TIMP3, a new potent multiple functional molecule, as a biotheropeutic tool to treat <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Adenovirus-mediated TIMP3 transduction in CT26 <z:hpo ids='HP_0003003'>colon cancer</z:hpo> model demonstrated multiple effects to arrest <z:e sem="disease" ids="C1516170" disease_type="Neoplastic Process" abbrv="">cancer cell growth</z:e> and induced massive <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>Also, adenovirally transferred TIMP3 reduced <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e>, migration and invasion behaviors of CT26 cells in vitro </plain></SENT>
<SENT sid="7" pm="."><plain>In vivo data showed that TIMP3 suppressed in vivo <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> and that <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> was significantly reduced by TIMP3 transduction </plain></SENT>
<SENT sid="8" pm="."><plain>This is the first systematic preclinical study to show that TIMP3 may be a potential molecular tool for <z:hpo ids='HP_0003003'>colon cancer</z:hpo> biological therapy </plain></SENT>
</text></document>